Antibiotic use and risk of multiple sclerosis

American Journal of Epidemiology

Volumn 163, Issue 11, 2006, Pages 997-1002

  Alonso, Alvaro ^a   Jick, Susan S ^b   Jick, Hershel ^b   Hernán, Miguel A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Anti bacterial agents; Chlamydophila pneumoniae; Multiple sclerosis; Prospective studies

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; DICLOXACILLIN; FLUCLOXACILLIN; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN V; PIVAMPICILLIN; TETRACYCLINE;

ANTIBIOTICS; BACTERIUM; BONE; ETIOLOGY; HARDENING; RISK FACTOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIPLE SCLEROSIS; NONHUMAN; SYMPTOMATOLOGY; UNITED KINGDOM;

ADULT; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EURASIA; EUROPE; UNITED KINGDOM; WESTERN EUROPE;

CHLAMYDOPHILA PNEUMONIAE;

EID: 33745606448     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj123     Document Type: Article

References (31)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. Layh-Schmitt G, Bendl C, Hildt U, et al. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann Neurol 2000;47:652-5.
3. Munger KL, Peeling RW, Hernán MA, et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 2003;14:141-7.
4. Dong-Si T, Weber J, Liu YB, et al. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. J Neurol 2004;251:542-7.
5. Boman J, Roblin PM, Sundstrom P, et al. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000;54:265.
6. Gieffers J, Pohl D, Treib J, et al. Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. Ann Neurol 2001;49:585-9.
7. Derfuss T, Gurkov R, Bergh FT, et al. Intrathecal antibody production against Chlamydia pneumonia in multiple sclerosis is part of a polyspecific immune response. Brain 2001;124:1325-35.
8. Saiz A, Marcos MA, Graus F, et al. No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis. J Neurol 2001;248:617-18.
9. Villoslada P, Juste C, Tintore M, et al. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology 2003;60:1944-8.
10. Kaufman M, Gaydos CA, Sriram S, et al. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler 2002;8:289-94.
11. Jackson LA, Grayston JT. Chlamydia pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone, 2000:2007-14.
12. Meier CR, Derby LE, Jick SS, et al. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999;281:427-31.
13. Brassard P, Bourgault C, Brophy J, et al. Antibiotics in primary prevention of stroke in the elderly. Stroke 2003;34:163-6.
14. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
15. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
16. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy 2003;23:686-9.
17. Hernán MA, Jick SS, Olek MJ, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. A prospective study. Neurology 2004;63:838-42.
18. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
20. Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 1994;36(S2):S180-S93.
21. Confavreux C. Infections and the risk of relapse in multiple sclerosis. Brain 2002;125:933-4.
22. Marrie RA, Wolfson C, Sturkenboom MC, et al. Multiple sclerosis and antecedent infections. A case-control study. Neurology 2000;54:2307-10.
23. Kozyrskyj AL, Dahl ME, Chateau DG, et al. Evidence-based prescribing of antibiotics for children: role of socioeconomic status and physician characteristics. CMAJ 2004;171:139-45.
24. Greenhalgh T, Gill P. Pressure to prescribe. BMJ 1997;315:1482-3.
25. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-51.
26. Munger KL, DeLorenze GN, Levin LI, et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two cohorts. Neurology 2004;62:1799-803.
27. Wolfson C, Talbot P. Bacterial infection as a cause of multiple sclerosis. Lancet 2002;360:352-3.
28. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7.
29. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80.
30. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128:1016-25.
31. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002;15:95-110.